Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -21.30% is 13% above its 5-year average of -24.37%, around the middle of its 5-year range (-31.99%–-7.37%).
28.98% above its 12-month average of -29.99%.
Reported quarterly return on assets; no daily interpolation. Q3 FY2026 (2026-06-30): -6.57%.
RETURN ON ASSETS (ROA)
-21.30%
RETURN ON ASSETS (ROA) AVG TTM
-29.99%
RETURN ON ASSETS (ROA) AVG 3Y
-30.23%
RETURN ON ASSETS (ROA) AVG 5Y
-24.37%
RETURN ON ASSETS (ROA) AVG 10Y
-6.74%
RETURN ON ASSETS (ROA) AVG 15Y
-0.18%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+28.98%
CURRENT VS 3Y AVG
+29.54%
CURRENT VS 5Y AVG
+12.59%
CURRENT VS 10Y AVG
-216.02%
CURRENT VS 15Y AVG
-11603.30%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+33.93%
vs the sector median at left
Enanta Pharmaceuticals, Inc.
Market Cap
$353.88M
Return on Assets (ROA)
-21.30%
TTM Avg
-29.99%
3Y Avg
-30.23%
5Y Avg
-24.37%
Market Cap
$353.00M
Return on Assets (ROA)
6.92%
TTM Avg
7.42%
3Y Avg
10.30%
5Y Avg
25.30%
Market Cap
$352.67M
Return on Assets (ROA)
-65.87%
TTM Avg
-110.74%
3Y Avg
-99.78%
5Y Avg
-89.00%
Market Cap
$355.36M
Return on Assets (ROA)
7.10%
TTM Avg
6.66%
3Y Avg
6.31%
5Y Avg
10.17%
Market Cap
$355.43M
Return on Assets (ROA)
-24.64%
TTM Avg
-45.98%
3Y Avg
-40.55%
5Y Avg
-44.33%
Market Cap
$349.70M
Return on Assets (ROA)
-51.02%
TTM Avg
-63.00%
3Y Avg
-53.19%
5Y Avg
-73.16%
Market Cap
$359.53M
Return on Assets (ROA)
-4.29%
TTM Avg
-7.44%
3Y Avg
-40.66%
5Y Avg
-49.61%
Market Cap
$346.73M
Return on Assets (ROA)
-49.80%
TTM Avg
-56.29%
3Y Avg
-75.47%
5Y Avg
-75.47%
Market Cap
$361.64M
Return on Assets (ROA)
-115.75%
TTM Avg
-127.38%
3Y Avg
-59.19%
5Y Avg
-98.90%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Enanta Pharmaceuticals, Inc. (ENTA) | $353.88M | -21.30% | -29.99% | -30.23% | -24.37% |
| Embecta Corp. (EMBC)vs › | $353.00M | 6.92% | 7.42% | 10.30% | 25.30% |
| Ocugen, Inc. (OCGN)vs › | $352.67M | -65.87% | -110.74% | -99.78% | -89.00% |
| Viemed Healthcare, Inc. (VMD)vs › | $355.36M | 7.10% | 6.66% | 6.31% | 10.17% |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $355.43M | -24.64% | -45.98% | -40.55% | -44.33% |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $349.70M | -51.02% | -63.00% | -53.19% | -73.16% |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $359.53M | -4.29% | -7.44% | -40.66% | -49.61% |
| Turn Therapeutics Inc. (TTRX)vs › | $346.73M | -49.80% | -56.29% | -75.47% | -75.47% |
| Opus Genetics, Inc. (IRD)vs › | $361.64M | -115.75% | -127.38% | -59.19% | -98.90% |
| Relmada Therapeutics, Inc. (RLMD)vs › | $344.04M | -28.27% | -117.81% | -109.90% | -91.03% |
ROA
-21.3%
ROE
-62.6%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-09-30 | -29.17% |
| 2024-09-30 | -30.81% |
| 2023-09-30 | -28.95% |
| 2022-09-30 | -31.99% |
| 2021-09-30 | -17.92% |
| 2020-09-30 | -7.37% |
| 2019-09-30 | 9.47% |
| 2018-09-30 | 17.37% |
| 2017-09-30 | 5.42% |
| 2016-09-30 | 7.70% |
| 2015-09-30 | 32.11% |
| 2014-09-30 | 22.16% |
| 2013-09-30 | 8.23% |
| 2012-09-30 | 41.02% |
| 2011-09-30 | 89.32% |
| 2010-09-30 | 0.00% |
